UCB, a global biopharmaceutical company announced key findings from the first retrospective patient cohort study in Denmark to observe the characteristics of patients selected for romosozumab treatment in routine clinical practice. The data were presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2024 in London. The observational, […]

The post Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY can help to close the treatment gap in osteoporosis first appeared on World Pharma Today.